Saad Mark E 4
4 · Axsome Therapeutics, Inc. · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Axsome (AXSM) Director Mark E. Saad Receives RSU Award
What Happened
Mark E. Saad, a director of Axsome Therapeutics (AXSM), received an award of 1,721 restricted stock units (RSUs) on June 5, 2026. The Form 4 reports the acquisition as a derivative award at $0.00 per unit (code A). The RSUs represent contingent rights to receive one share of common stock per RSU and have no immediate cash cost to the insider.
Key Details
- Transaction date: 2026-06-05 (reported on Form 4 filed 2026-06-09).
- Security/details: 1,721 RSUs granted (derivative award) at $0.00 per unit.
- Vesting: RSUs vest in full on the one-year anniversary of the grant (per footnote).
- Shares owned after transaction: Not specified in the provided filing.
- Timeliness: Form 4 was filed on 2026-06-09, within the SEC’s standard two-business-day reporting window for insider transactions (timely).
- Transaction code: A = Award/Grant.
Context
RSUs are a form of equity compensation that convert into shares only when vested; this grant does not represent an immediate open-market purchase or sale. Grants to directors are common as compensation and do not, by themselves, signal a buy or sell decision until vested or sold.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-06-05+1,721→ 1,721 total→ Common Stock (1,721 underlying)
Footnotes (2)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The RSUs vest in full on the one-year anniversary of the date of grant.